These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37645162)

  • 1. Can detection and prediction models for Alzheimer's Disease be applied to Prodromal Parkinson's Disease using explainable artificial intelligence? A brief report on Digital Neuro Signatures.
    Tarnanas I; Vlamos P; Harms DR;
    Open Res Eur; 2021; 1():146. PubMed ID: 37645162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Making pre-screening for Alzheimer's disease (AD) and Postoperative delirium among post-acute COVID-19 syndrome - (PACS) a national priority: The Deep Neuro Study.
    Tarnanas I; Tsolaki M
    Open Res Eur; 2022; 2():98. PubMed ID: 37767224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prediagnostic phase of Parkinson's disease.
    Noyce AJ; Lees AJ; Schrag AE
    J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):871-8. PubMed ID: 26848171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Making Pre-screening for Alzheimer's Disease (AD) and Postoperative Delirium Among Post-Acute COVID-19 Syndrome (PACS) a National Priority: The Deep Neuro Study.
    Tarnanas I; Tsolaki M
    Adv Exp Med Biol; 2023; 1424():41-47. PubMed ID: 37486477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methodological Issues in Randomized Clinical Trials for Prodromal Alzheimer's and Parkinson's Disease.
    de Aquino CH
    Front Neurol; 2021; 12():694329. PubMed ID: 34421799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Concept of Prodromal Parkinson's Disease.
    Mahlknecht P; Seppi K; Poewe W
    J Parkinsons Dis; 2015; 5(4):681-97. PubMed ID: 26485429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circuit imaging biomarkers in preclinical and prodromal Parkinson's disease.
    Meles SK; Oertel WH; Leenders KL
    Mol Med; 2021 Sep; 27(1):111. PubMed ID: 34530732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multilayer multimodal detection and prediction model based on explainable artificial intelligence for Alzheimer's disease.
    El-Sappagh S; Alonso JM; Islam SMR; Sultan AM; Kwak KS
    Sci Rep; 2021 Jan; 11(1):2660. PubMed ID: 33514817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Externally validated deep learning model to identify prodromal Parkinson's disease from electrocardiogram.
    Karabayir I; Gunturkun F; Butler L; Goldman SM; Kamaleswaran R; Davis RL; Colletta K; Chinthala L; Jefferies JL; Bobay K; Ross GW; Petrovitch H; Masaki K; Tanner CM; Akbilgic O
    Sci Rep; 2023 Jul; 13(1):12290. PubMed ID: 37516770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.
    Cavedo E; Lista S; Khachaturian Z; Aisen P; Amouyel P; Herholz K; Jack CR; Sperling R; Cummings J; Blennow K; O'Bryant S; Frisoni GB; Khachaturian A; Kivipelto M; Klunk W; Broich K; Andrieu S; de Schotten MT; Mangin JF; Lammertsma AA; Johnson K; Teipel S; Drzezga A; Bokde A; Colliot O; Bakardjian H; Zetterberg H; Dubois B; Vellas B; Schneider LS; Hampel H
    J Prev Alzheimers Dis; 2014 Dec; 1(3):181-202. PubMed ID: 26478889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges of modifying disease progression in prediagnostic Parkinson's disease.
    Salat D; Noyce AJ; Schrag A; Tolosa E
    Lancet Neurol; 2016 May; 15(6):637-48. PubMed ID: 26993435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease.
    Lim NS; Swanson CR; Cherng HR; Unger TL; Xie SX; Weintraub D; Marek K; Stern MB; Siderowf A; ; ; Trojanowski JQ; Chen-Plotkin AS
    Ann Clin Transl Neurol; 2016 May; 3(5):346-55. PubMed ID: 27231704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediagnostic presentations of Parkinson's disease in primary care: a case-control study.
    Schrag A; Horsfall L; Walters K; Noyce A; Petersen I
    Lancet Neurol; 2015 Jan; 14(1):57-64. PubMed ID: 25435387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive-motor dual-task interference in Alzheimer's disease, Parkinson's disease, and prodromal neurodegeneration: A scoping review.
    Longhurst JK; Rider JV; Cummings JL; John SE; Poston B; Landers MR
    Gait Posture; 2023 Sep; 105():58-74. PubMed ID: 37487365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Explainable machine learning models based on multimodal time-series data for the early detection of Parkinson's disease.
    Junaid M; Ali S; Eid F; El-Sappagh S; Abuhmed T
    Comput Methods Programs Biomed; 2023 Jun; 234():107495. PubMed ID: 37003039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers of Parkinson's disease: 20 years later.
    Yilmaz R; Hopfner F; van Eimeren T; Berg D
    J Neural Transm (Vienna); 2019 Jul; 126(7):803-813. PubMed ID: 30949837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of the Movement Disorders Society criteria for prodromal Parkinson's disease: A population-based 10-year study.
    Mahlknecht P; Gasperi A; Djamshidian A; Kiechl S; Stockner H; Willeit P; Willeit J; Rungger G; Poewe W; Seppi K
    Mov Disord; 2018 Mar; 33(3):405-413. PubMed ID: 29436728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prodromal Parkinson's disease: hype or hope for disease-modification trials?
    Mahlknecht P; Marini K; Werkmann M; Poewe W; Seppi K
    Transl Neurodegener; 2022 Feb; 11(1):11. PubMed ID: 35184752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerating diagnosis of Parkinson's disease through risk prediction.
    Yuan W; Beaulieu-Jones B; Krolewski R; Palmer N; Veyrat-Follet C; Frau F; Cohen C; Bozzi S; Cogswell M; Kumar D; Coulouvrat C; Leroy B; Fischer TZ; Sardi SP; Chandross KJ; Rubin LL; Wills AM; Kohane I; Lipnick SL
    BMC Neurol; 2021 May; 21(1):201. PubMed ID: 34006233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of gait control assessed by cognitive-motor dual-tasks: pros and cons in detecting people at risk of developing Alzheimer's and Parkinson's diseases.
    Belghali M; Chastan N; Cignetti F; Davenne D; Decker LM
    Geroscience; 2017 Jun; 39(3):305-329. PubMed ID: 28551877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.